165 related articles for article (PubMed ID: 35098667)
1. Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective.
Bae S; Brnabic A; Crowe P; Carey-Smith R; Andelkovic V; Singhal N; Stalley P; Yip D; Desai J
Asia Pac J Clin Oncol; 2022 Dec; 18(6):605-613. PubMed ID: 35098667
[TBL] [Abstract][Full Text] [Related]
2. Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services.
Bae S; Crowe P; Gowda R; Joubert W; Carey-Smith R; Stalley P; Desai J
Clin Sarcoma Res; 2016; 6():11. PubMed ID: 27403280
[TBL] [Abstract][Full Text] [Related]
3. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Bilici A; Koca S; Karaagac M; Aydin SG; Eraslan E; Kaplan MA; Ocak B; Goksu SS; Paydas S; Akgul F; Derin S; Ergun Y; Yekeduz E; Erol C; Ozyukseler DT; Demiray AG; Karaca M; Guc ZG; Menekse S; Cinkir HY; Gumusay O; Sakin A; Ozkul O; Demir H; Erdem D; Besiroglu M; Unal OU; Acar R; Koral L; Sahin S; Sakalar T; Bahceci A; Ozveren A; Gunaydin UM; Seker MM; Sunar V; Dal P; Artac M; Turhal S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8243-8253. PubMed ID: 37067546
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
7. A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.
Wagner MJ; Amodu LI; Duh MS; Korves C; Solleza F; Manson SC; Diaz J; Neary MP; Demetri GD
BMC Cancer; 2015 Mar; 15():175. PubMed ID: 25885530
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas.
Parikh RC; Lorenzo M; Hess LM; Candrilli SD; Nicol S; Kaye JA
Clin Sarcoma Res; 2018; 8():8. PubMed ID: 29744029
[TBL] [Abstract][Full Text] [Related]
9. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials.
Nassif EF; Blay JY; Massard C; Dufresne A; Brahmi M; Cassier P; Ray-Coquard I; Pautier P; Leary A; Sunyach MP; Bahleda R; Levy A; Le Pechoux C; Honoré C; Mir O; Le Cesne A
ESMO Open; 2022 Apr; 7(2):100425. PubMed ID: 35255445
[TBL] [Abstract][Full Text] [Related]
10. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
Maurel J; Buesa J; López-Pousa A; del Muro XG; Quintana MJ; Martín J; Casado A; Martínez-Trufero J; de Las Peñas R; Balañá C
J Surg Oncol; 2004 Oct; 88(1):44-9. PubMed ID: 15384088
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
12. Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma.
Pan M; Zhou MY; Jiang C; Zhang Z; Bui NQ; Bien J; Siy A; Achacoso N; Solorzano AV; Tse P; Chung E; Thomas S; Habel LA; Ganjoo KN
Clin Cancer Res; 2024 Jan; 30(2):413-419. PubMed ID: 37831066
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting prognosis and treatment strategies in metastatic soft tissue sarcomas: twenty years of experience.
İlhan A; Eraslan E; Yildiz F; Arslan ÜY; Alkiş N
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6465-6472. PubMed ID: 34787850
[TBL] [Abstract][Full Text] [Related]
14. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.
Savina M; Le Cesne A; Blay JY; Ray-Coquard I; Mir O; Toulmonde M; Cousin S; Terrier P; Ranchere-Vince D; Meeus P; Stoeckle E; Honoré C; Sargos P; Sunyach MP; Le Péchoux C; Giraud A; Bellera C; Le Loarer F; Italiano A
BMC Med; 2017 Apr; 15(1):78. PubMed ID: 28391775
[TBL] [Abstract][Full Text] [Related]
15. Update on systemic therapy for advanced soft-tissue sarcoma.
Smrke A; Wang Y; Simmons C
Curr Oncol; 2020 Feb; 27(Suppl 1):25-33. PubMed ID: 32174755
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
17. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.
Kasper B; Ouali M; van Glabbeke M; Blay JY; Bramwell VH; Woll PJ; Hohenberger P; Schöffski P
Eur J Cancer; 2013 Jan; 49(2):449-56. PubMed ID: 22975215
[TBL] [Abstract][Full Text] [Related]
19. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study.
Bonvalot S; Wunder J; Gronchi A; Broto JM; Turcotte R; Rastrelli M; Papai Z; Radaelli S; Lindner LH; Shumelinsky F; Cubillo A; Rutkowski P; Demaire C; Strens D; Nalbantov G
Eur J Surg Oncol; 2021 Aug; 47(8):2166-2172. PubMed ID: 33676792
[TBL] [Abstract][Full Text] [Related]
20. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
